Figure 1.
Treatment flow-chart of all the multidisciplinary treatment options that patients had received.
Figure 2.
Disposition of subjects at the time of data cut-off and analysis.
Table 1.
(KRAS mutant) Patient and Disease Characteristics at Baseline.
Table 2.
Median number of lines of treatments that patients had received.
Table 3.
The frequency of oxaliplatin-based regimens used in either locally advanced, metastatic or both stages between KRAS mutant and wild-type patients.
Figure 3.
Overall survival (OS) in KRAS mutant mCRC patients who had used and never-used oxaliplatin-based regimens.
Figure 4.
Overall survival (OS) in KRAS wild-type mCRC patients who had used and never-used oxaliplatin-based regimens.
Table 4.
Cox proportional hazard model for OS in KRAS mutant mCRC patients.
Table 5.
Cox proportional hazard model for OS in KRAS wild-type mCRC patients.
Table 6.
Median time to recurrence (TTR) and the percentage of TTR less and more than 6 months after adjuvant oxaliplatin-based regimens between KRAS mutant and wild-type patients.